Standard insulin aspart will lead insulin aspart sales through 2036 with 62.0% share in 2026. Prefilled pens represent 57.0% share. Market value is estimated at USD 3.78 billion in 2025 and is projected to reach USD 5.46 billion by 2036, adding USD 1.55 billion between 2026 and 2036.